Dow breaches 27,000; healthcare in spotlight after Trump's decision on rebate

NEW YORK (Reuters) – The S&P 500 was little changed in afternoon trading on Thursday, with healthcare stocks mixed after the Trump administration withdrew a rule that would kill rebates.

Traders work on the floor at the New York Stock Exchange (NYSE) in New York, U.S., July 1, 2019. REUTERS/Brendan McDermid

Shares of pharmacy benefit managers gained as the news meant these companies would continue to benefit from after-market discounts from drugmakers. Health insurers and drug distributors also rose.

A 5.3% gain in UnitedHealth Group Inc (UNH.N) helped the Dow break above 27,000 points for the first time. Cigna Corp (CI.N) surged 9%.

At the same time, drugmakers such as Merck & Co Inc (MRK.N) and Pfizer Inc (PFE.N) dropped and the Nasdaq biotech index .NBI fell 1.7%. The healthcare index .SPXHC was down 0.3%.

Helping to support stocks were comments from Federal Reserve Chairman Jerome Powell, which boosted expectations for an interest-rate cut.

Powell, in his first day of testimony before Congress on Wednesday, confirmed the U.S. economy was still under threat from disappointing factory activity, tame inflation and a simmering trade war and said the Fed stood ready to “act as appropriate.” Powell testified before the Senate Banking Committee on Thursday.

The S&P 500 rose above the 3,000 level for the first time Wednesday following the news and hit a high of 3,002.33 on Thursday, but the index has been able to hold above that level.

“The fact that the market has tried several times this week to get through it and hold has been a big psychological negative,” said Michael James, managing director of equity trading at Wedbush Securities in Los Angeles.

The Dow Jones Industrial Average .DJI rose 174.03 points, or 0.65%, to 27,034.23, the S&P 500 .SPX gained 1.97 points, or 0.07%, to 2,995.04 and the

Read More Here...

Bookmark the permalink.